Variations in the Plasma Cholesterol and Cholesterol Ester Content in Hog Cholera

Shope, Richard E.

doi:10.1084/jem.51.2.179

Cited by 2 publications

(1 citation statement)

References 5 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cholesterol is known to have a causal link to inflammatory diseases and its oxidised metabolites (oxysterols) alter adaptive and innate immunity, and innate immune signalling has been shown to modulate the dynamics of cholesterol homeostasis [ 62 – 64 , 87 ]. In this connection, over the last century, natural and experimental infection studies have reported for a wide range of pathogens a state of hypocholesterolemia during the acute phase (2–4 days) of infection that is often followed by a rebound period of hypercholesterolemia [ 88 – 96 ]. Currently in the critical care of sepsis, monitoring of cholesterol levels is used as a biomarker for prognosis.…”

Section: Lipogenic Requirement and Immune Regulationmentioning

confidence: 99%

Infection homeostasis: implications for therapeutic and immune programming of metabolism in controlling infection

Kotzamanis

Angulo

Ghazal

2015

Med Microbiol Immunol

View full text Add to dashboard Cite

Homeostasis underpins at a systems level the regulatory control of immunity and metabolism. While physiologically these systems are often viewed as independent, there is increasing evidence showing a tight coupling between immune and metabolic functions. Critically upon infection, the homeostatic regulation for both immune and metabolic pathways is altered yet these changes are often investigated in isolation. Here, we summarise our current understanding of these processes in the context of a clinically relevant pathogen, cytomegalovirus. We synthesise from the literature an integrative view of a coupled immune–metabolic infection process, centred on sugar and lipid metabolism. We put forward the notion that understanding immune control of key metabolic enzymatic steps in infection will promote the future development of novel therapeutic modalities based on metabolic modifiers that either enhance protection or inhibit infection.

show abstract